Abstract
Overview of Therapeutic Clinical Intelligence Report Series
Austin Research Group' s Therapeutic Clinical Intelligence Report Series
provides clients within the pharmaceutical and biotechnology industry with
detailed information and analysis of competitive products in the development
pipeline. Reports contain synthesized information and analysis of clinical
development activities for key marketed and pipeline products within multiple
therapeutic categories and generally include the following data points:
- Product Overview: Mechanism of Action, Developing Companies, Indications
and Phase of Development.
- Clinical Trial Assessments: Detailed evaluations of completed and ongoing
competitor studies that capture key elements of the study protocol including:
- Trial design
- Start and end dates
- Study size and patient type
- Number of participating sites
- Dosing regimen
- Endpoints
- Safety and efficacy results
Clients utilize the report as an resource to support key decisions including:
- Analyzing the overall depth and breadth of the competitive landscape
within a therapeutic area
- Assessing target product profiles of key current and future competitors
- Benchmarking competitor clinical trial designs and results
- Developing clinical analogues to support go-no-go decisions
- Identifying clinical hurdles posed by competitors
- Designing clinical trials more effectively to maximize a product' s
penetration
Scope of Research & Analysis
- The scope of this research focuses on the research and development
pipeline for Type-2 diabetes non-insulin therapeutics.
- Specifically, this report examines the 35 most promising compounds in
Phase 2, Phase 3, and Registration stages of development.
- This report provides detailed analysis of the product profiles and
clinical trials involving 35 of these novel agents.
View Cart
